ICI Innovation of the Year 2018 Runner up

BioGenCell has developed a long-term road map for the next five years and beyond.
Our goal is to reach commercialization of the first product based on FDA’s and EMA’s expedited programs while developing a pipeline of additional products based on our technology platform.
A phase I/II multi-centered randomized-controlled-study in 40 patients was approved in Israel and in Belgium. This will be followed by a pivotal phase III study.
A market leading position in bringing stem cell treatments to patients in every clinic will be achieved due to the technology’s superior safety and scalability. BioGenCell will add value and open a competitive gap by creating a revenue stream based on FDA’s and EMA’s expedited programs. By the end of the clinical trials, the company will have developed strategic partnerships and distribution channels.

Skip to content

Manage Consent

We use cookies for essential operations, improving your experience, anonymous analytics, and personalized ads. You can allow all categories or fine-tune each one. Learn more: Privacy Policy